**Science and Art of Determining the Association and Causation of Adverse Events in Pharmacovigilance: Techniques and Difficulties**

Sachin Kumar1, PhD, Saurabh Chaturvedi1, PhD, Rashi Gupta1, PhD, Shravan Kumar2, PhD, Harshit Singh3, PhD

1Department of Medical Laboratory Technology, School of Allied Health Sciences, Delhi Pharmaceutical Sciences and Research University, New Delhi, India

2 Pharma Talk Research Foundation

3 Immuno biology Lab, Translational Health Science and Technology Institute, Faridabad, Haryana, India

**ABSTRACT**

Numerous medications are available in the healthcare sector, and the number is growing daily. Since life style changes have significantly increased medicine use, safer pharmaceuticals are urgently needed. To keep things under control, regulators and other authorities have put in place strict regulations and a pharmacovigilance system. The most difficult pharmacovigilance task is establishing causality between adverse occurrences and suspicious medications. Adverse medication reactions can range from minor to life-threatening, causing discomfort or significant morbidity and mortality. It necessitates careful assessment of the patient's underlying medical issues, co-suspect medications, patient-related factors, and adverse events. While reporting of adverse drug reactions (ADRs) has increased over the past few years. The determination of the likelihood of a medicine being responsible for an adverse event, and this is arguably the crucial role in running each nation's national pharmacovigilance programme. It seeks to establish a link between the incidence of an adverse event and the administration of a medicine. Accurate causal assessment is critical for a variety of stakeholders, including healthcare practitioners, regulatory bodies, and pharmaceutical corporations, because it guides drug safety decision-making processes. In pharmacovigilance, determining causality is a routine process. Despite the enormous number of approaches that have been proposed, determining a drug's causal contribution to the development of an adverse event continues to be one of the most disputed issues. All of these techniques were divided into three major groups: algorithms, probabilistic techniques (Bayesian approaches), and expert judgment/global introspection. Due to issues with validity and reproducibility, no one method is regarded as the best. Each technique uses a distinct set of causality categories, and each method uses a different set of evaluation criteria to evaluate the categories. When determining new signals, measuring the weight of the evidence, and assessing the benefit-risk profile of pharmaceutical medicines, causality is the crucial aspect.

**Keywords:** Adverse event, Pharmacovigilance, causality assessment

**1.Introduction**

In 1960s Thalidomide disaster and numerous other recent drug market withdrawals have resulted in recognizing adverse drug reactions (ADR) as one of the primary factors that results in morbidity and mortality by healthcare professionals and the general public **[1].** After this catastrophe, the US FDA changed its legislation to include stricter criteria for pharmaceutical approvals and a spontaneous reporting PV system to track the occurrence of adverse drug reactions in the healthcare industry **[2].** ADRs are responsible for hospital admissions, extended hospital stays, and fatalities. ADR-related inpatient hospitalizations have ranged from 4.8% in Germany, 6.5% in the UK, to 7.3% in the United States **[3]**. Up to 6.5% of all hospital admissions in the United Kingdom were associated with ADRs, while the overall fatality rate was 0.15% **[4].** According to studies, between 2.4% and 30% of hospitalized patients could have an ADR during their hospitalization **[5]**. The prevalence of fatal ADR ranged from 0% to 5.2% in a recent meta-analysis **[6-7]**. ADRs also have negative effects on quality of life and the loss of economic resources **[5]**, **[8]**. According to studies done in India, hospitalized patients are believed to experience suspected ADRs at a rate of between 2% and 3% **[9].** The median incidence of ADRs that resulted in hospitalizations and those that occurred while in the hospital was assessed to be 2.85% and 6.34%, respectively, by a systematic study **[10].**

Causality evaluation, which aims to identify the cause-and-effect relationship between a medication or medical practice and an adverse event, is a crucial part of pharmacovigilance. It is essential for assessing the safety profile of medications and guaranteeing patient welfare. However, pharmacovigilance's causation evaluation procedure continues to be difficult and complex **[11].** The complex nature of the human body, a lack of knowledge, under-reporting and reporting bias, a variety of evaluation methods, and challenges related to uncommon events and long-term impacts are only a few of the reasons that contribute to this challenge. These problems need to be fixed in order to improve patient safety and the precision and dependability of causality assessment in the area of pharmacovigilance **[12].**

The Causality assessment techniques were divided into three major groups: algorithms, probabilistic techniques (Bayesian approaches), and expert judgment/global introspection **(Figure 1).** The majority of reported instances are classified as suspected ADRs in pharmacovigilance. Drug rechallenges (i.e., when the suspected drug was reintroduced into the patient's medication or the patient had previously taken the same suspected drug) are rare because, in most cases, ADRs are not distinct to each drug. It is requested that consumers and healthcare professionals report any incidents they believe to be connected to drug use. To address this issue, health authorities have developed systematic and uniform methods for causality assessment, categorizing ADR reports in accordance with one of the causality gradations recommended by the WHO-UMC causality evaluation system **[13].** Apart from ADR identification, where novel approaches have been put forth **[14],** causality assessment an essential component of signal detection, which is done by health authorities and is defined as "reported information on a possible causal relationship between an adverse event and a drug, the relationship being unknown or inadequately documented previously," is causality assessment, which helps with the risk-benefit analysis of commercially available medications **[13]**.

**2.Why measure causality in Pharmacovigilance?**

The majority of case reports in pharmacovigilance involve alleged adverse medication responses, which is a problem in and of itself. Drug-specific adverse effects are uncommon, diagnostic testing is typically deficient, and re-challenge is infrequently ethically acceptable. The majority of adverse responses are either "possible" or "probable" in nature; very few are "certain" or "unlikely" in actuality. Many approaches for an organized and unified assessment of causation have been created in an effort to address this issue **[15].** However, it hasn't been demonstrated that any of these algorithms can generate an accurate and trustworthy quantitative evaluation of relationship likelihood. However, causality evaluation has developed into a typical, standard approach in pharmacovigilance. **In Table 1,** the developments and restrictions of causality assessment are discussed **[16].**

**Table 1. Standardized case causality assessment developments and restrictions**

|  |  |
| --- | --- |
| **What causality assessment can do** | **What causality assessment cannot do** |
| Decrease disagreement between assessors | Give accurate quantitative measurement of relationship likelihood |
| Classify relationship likelihood | Distinguish valid from invalid cases |
| Mark individual case reports | Prove the connection between drug and event |
| Improvement of scientific evaluation; educational | Quantify the contribution of a drug to the development of an adverse event |
|  | Change uncertainty into certainty |

Causality Assessment Tools

Expert Judgement

(Global Inspection)

Probabilistic Method

(Logistic Method)

Algorithm Methods

**Figure 1: Types of causality assessment tools.**

**3.Need for Relatedness/causality Evaluation**

Evaluation of causality is crucial in all facets of medical practice. Finding the offending medication or substances may save a life or help to limit further harm the drug causes to our biological systems. Since the underlying ailment might present in the same way as the drug when a patient is taking multiple medications, it can be challenging to pinpoint which medication is responsible for a drug reaction. Unfortunately, there are no specific diagnostic procedures. Although histology can help in the identification of drug reactions, it is not enough to point to a specific substance. However, identifying the precise medicine is critical since it directly influences a clinician's decision to continue or discontinue drugs. This can be important in some circumstances, hence proving causality with almost perfect accuracy is preferred. Clinical trial participants, employees of the pharmaceutical sector, academics, and regulatory bodies can all undertake causality analyses in a number of circumstances **[17].**

**4.Principles for determining causality**

All approaches or tools for evaluating causality comply to the following four essential ADR diagnosis principles: (i) the temporal relationship between the drug and the drug reaction; (ii) biological plausibility; (iii) dechallenge; and (iv) rechallenge. Positive or negative prechallenge is the term used when dechallenge or rechallenge has previously taken place **[18]**.

Ihtisham K et al. 2019 found that various HLA alleles in North Indians had significant connections to CBZ and PHT that required testing prior to the start of an AED; simply screening for HLA-B\*15:02 may not be effective in this community **[19]**.

A 12-year-old child who complained of having erythematous, macular rashes all over his body, including his face, neck, chest, both upper and lower limbs, and abdomen, was admitted to the hospital in 2018. According to the patient's history, the patient had experienced vomiting, nausea, and fever three days ago. He developed conjunctivitis and angioedema the next day, and he was admitted to the hospital as a result of erythematous lesions all over his body, oral ulcers, and crustations on the angle of his mouth. The patient was identified as a newly diagnosed epileptic who was receiving 100 mg of carbamazepine for seizures based on his prescription history. On the eighth day of carbamazepine therapy, the child had erythematous lesions and macular rashes all over their body, which gradually increased to cover 60% of their body surface area. The use of carbamazepine has decreased. The final diagnosis was Stevens-Johnson syndrome brought on by carbamazepine **[20].**

Dexamethasone and cefotaxime were given intravenously, Betamethasone was applied topically, Clotrimazole mouthwash was used to treat oral ulcers, Tobramycin eye drops were used to treat ocular lesions, IV fluids were given, and additional supportive measures were used. After 7 days in the hospital, the patient improved and was discharged. Case-control research found that short-term carbamazepine use increases the incidence of SJS for fewer than 8 weeks. In this scenario, the offending medicine should be discontinued **[21].** Using Naranjo's approach **[22]** and the WHO-UMC Scale, a causality analysis was conducted, and the current ADR was found to be 'PROBABLE' with carbamazepine. The reaction was SEVERE (Level 6) on the modified Hartwig and Siegel severity scale, but "PROBABLY PREVENTABLE" on the modified Schumock and Thornton scale **[23].**

In previous studies dermatologists diagnosed SJS, SJS-TEN overlap, and TEN using diagnostic criteria developed by **Roujeau et al.** **[24]** and the severe cutaneous adverse reactions (SCAR) study classification developed by **Batsuji-Garin et al.** **[25]** Cases having SJS, SJS-TEN overlap, or TEN were categorized as SJS/TEN. The causal relationship between CBZ and SJS/TEN was established using the ALDEN score of 6 or higher **[26].**

**5.Methods of Causality Assessment**

The timing between the administration of the drug and the occurrence of the adverse drug reaction (ADR), the search for non-drug related causes, the confirmation of the reaction through in vivo or in vitro tests, and prior knowledge of similar events connected to the suspected drug or its therapeutic class, among other criteria, are just a few of the criteria that numerous researchers developed numerous techniques for determining the cause of adverse drug reactions (ADRs) **[27].** However, due to the lack of established diagnostic criteria or categories, there may be significant inter- and intra-rater variability **[28].** There is currently no procedure for determining the cause of ADRs that is recognized worldwide **[29].**

Clinical judgement, probabilistic approaches and algorithms are the broad categories of causality evaluation methodologies. Each area contains tools and approaches for determining the likelihood of a drug-adverse event relationship. Expert opinions are distinctive judgements made without the aid of a standardized technique to establish causality, based on prior knowledge and experience in the field. Algorithms, which are collections of particular questions with related scores, can be used to assess the likelihood of a cause-and-effect relationship. Bayesian approaches take advantage of specific outcomes in a case to transform a prior probability estimate into a posterior probability estimate of drug causation. The data in each specific example is combined with this previous knowledge in the posterior probability to derive an estimate of causality. The epidemiology data are used to calculate the prior probability. Due to issues with validity and reproducibility, no one method is regarded as the best. Several causality assessment methods are available. Different tools and methods used for causality assessment and their key features described in **Table 2.**

**Table 2. Different tools and methods used for causality assessment and their key features.**

|  |  |  |
| --- | --- | --- |
| **Methods of causality assessment tools** | **Advantages** | **Limitations** |
| **Naranjo et al. (1981)** | * A method based on structured questionnaires
* A numerical rating indicating likelihood widely acknowledged
 | * Relies on proper information reporting and is only applicable in certain circumstances
* Some inquiries could be unclear.
 |
| **Koh et al. (2008)** | * Uses a methodical, objective procedure
* Incorporates a number of aspects
 | * Requires precise and thorough clinical data
* Complex cases might not be handled well-defined to particular situations
 |
| **Karch and Lasagna (1977)** | * Established standards-based methodology
* Offers category evaluation
 | * Individual interpretation
* precise quantitative recommendations
* Complex cases might not be handled well.
 |
| **Kramer et al. (1979)** | * An algorithm to evaluate the relationship between drugs and events
 | * Restricted to particular situations
* Complex cases might not be handled well.
* For a final determination, additional evidence might be needed.
 |
| **Begaud (1984)** | * A methodical technique to evaluating causality
* Analyses a variety of aspects
 | * Implementation could be challenging
* Interpretation that is subjective
* Limited quantitative guidance
 |
| **WHO – Uppsala monitoring center-causality assessment 1994** | * Widespread, easy to use and considers a variety of aspects
 | * Interpretation that is subjective and little quantitative evidence
* Complex cases might not be handled well.
 |

**5.1Expert Judgement/Global Introspection**

According to Hoskins et al. (1992), either a physician or a clinical investigator suspects or recognizes about 80% of adverse occurrences. Clinical pharmacologists or treating physicians are the ones who suspect or identify ADRs the **most [30].** This expert judgement, also known as global introspection, is the process by which an expert expresses their opinion regarding potential drug causation by taking into account all information pertinent to a suspected ADR **[31]** estimating their relative importance, and allocating weights to determine the likelihood that the drug played a part in the unfavourable event **[30].** ADR in this area is evaluated by either one expert assessor or a team of experts. There is disagreement and significant inter-rater variability since these experts' appraisal and assessment of ADR are solely based on their individual expertise and experience of the topic of concern. Here, we outline two techniques based on professional judgement.

**5.1.1Swedish Causality Assessment Method (Wilholm et al. 1984)**

The Swedish regulatory body bases its causation assessment methodology on the opinions of an expert committee. The clinician considers seven important factors when determining whether a relationship is causal: (i) temporal relationship (ii) previous drug knowledge, (iii) dosage connection, (iv) drug response pattern, (v) readministration, (vi) alternative etiological possibilities, and (vii) concurrent medications. If causality has been proven, adverse medication responses are classified as "probable" or "possible" and "non-assessable" or "unlikely" **(Wiholm et al., 1984).** The method's limitation in the categories that causation can be subdivided could lead to overlap and inappropriate evaluation of ADRs **[32]**.

**5.1.2Causality Assessment criteria of WHO-UMC**

The most frequently used criteria for determining the causation of adverse events in pharmacovigilance are those developed by the WHO-UMC. These scales offer an appropriate and useful method for determining the likelihood that a specific reaction can be a drug's input **[33]**. **Rehan et al. (2009)** claim that the WHO-UMC method is used as a helpful tool for assessing safety case reports. By contrasting the patient history and the calibre of the case safety report, the clinical-pharmacological characteristics of the medication can be evaluated **[34]**. **Table 3** lists the several causality categories.

The four factors listed below are part of the WHO-UMC causality evaluation technique **[34]:**

a) The time period between taking a drug and experiencing a side effect.

b) The absence of other elements, such as medications or illnesses that are present simultaneously.

c) Dechallenge, an adverse drug withdrawal or dosage lowering reaction.

d) The response to medication administration after dechallenge. (rechallenge)

Six categories that depend on several of the aforementioned requirements being met are used to classify the level of causal relationship. When all four requirements are satisfied, the causal category is considered "certain." When conditions a, b, and c are satisfied, it is "probable." The occurrence is classified as "possible" when just requirement a is satisfied, and as "unlikely" when both criterion a and b are not met **(Table 4).** In addition to these four categories, ADR can also be characterized in the WHO-UMC causality assessment as "Unclassified/Conditional" or "Unassessable/Unclassifiable." When further information is required and such information is either being sought out or is already being examined, the phrase "Unclassified/Conditional" is used. The judgement is "Unclassifiable" when a report contains inconsistent or incomplete material that cannot be validated or supplemented. The WHO-UMC approach can be used to identify drug-drug interactions by analyzing the interacting drug in the medical context of the patient, which changes the pharmacokinetic or pharmacodynamics of the non-interacting drug.

**Table 3. Causality categories developed by the WHO-UMC**

|  |  |
| --- | --- |
| **Causality term** | **Criteria for Assessment**  |
| Certain | * Event or laboratory test abnormality, with plausible time relationship to drug intake
* Cannot be explained by disease or other drugs
* Response to withdrawal plausible (pharmacologically, pathologically)
* Event definitive pharmacologically or phenomenologically (i.e., an objective and specific medical disorder or a recognized pharmacologic phenomenon)
* Rechallenge satisfactory, if necessary
 |
| Probable/likely | * Event or laboratory test abnormality, with reasonable time relationship to drug intake
* Unlikely to be attributed to disease or other drugs
* Response to withdrawal clinically reasonable
* Rechallenge not required
 |
| Possible | * Event or laboratory test abnormality, with reasonable time relationship to drug intake
* Could also be explained by disease or other drugs
* Information on drug withdrawal may be lacking or unclear
 |
| Unlikely | * Event or laboratory test abnormality, with a time to drug intake that makes a relationship improbable (but not impossible)
* Disease or other drugs provide plausible explanation
 |
| Conditional/unclassified | * Event or laboratory test abnormality
* More data for proper assessment needed, or
* Additional data under examination
 |
| Unassessable/unclassifiable | * Report suggesting an adverse reaction
* Cannot be judged because information is insufficient or contradictory
* Data cannot be supplemented or verified
 |

**Table 4. The WHO- UMC causality assessment method includes 4 criteria’s**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Type of causality** | **Temporal relationship** | **Other drugs/disease ruled out** | **Dechallenge** | **Rechallenge** |
| Certain | Yes | Yes | Yes | Yes |
| Probable | Yes | Yes | Yes | No |
| Possible | Yes | No | No | No |
| Unlikely | No | No | No | No |

Dechallenge is the therapeutic choice to stop taking a medication after it may have caused an adverse pharmacological reaction. Dechallenge are classified as "positive" or "suggestive" if the reaction disappears completely or partially once the drug is withdrawn, and "negative" or "against" if the reaction persists. Rechallenge simply means giving a patient who has previously experienced an unpleasant event or an ADR that may have been medication-related another dose (or doses) of the same medication, whether on purpose or mistakenly. Negative rechallenge occurs when the product is reintroduced and fails to produce the same signs and symptoms that were seen when the suspect drug was first introduced, while positive rechallenge occurs when the same signs and symptoms return after the suspect product is reintroduced **[35].**

**5.2Algorithms**

According to **Lanctot KL et al. (1994),** an algorithm is a flow chart with specific instructions on how to solve a particular problem **[36]**. When an ADR is suspected, there is a clinical tool in the form of a questionnaire that offers exact operational criteria for determining the likelihood of cause. Algorithms provide structured and standardized methods of assessment in a systematic approach to identifying ADRs based on characteristics including the temporal sequence or time to the commencement of the ADR, previous drug/adverse response history, and dechallenge and rechallenge. Because each situation is treated methodically, there is a high level of uniformity and reproducibility. To reach a judgement, however, clinical discretion is needed at different points **[37]**. There are numerous computational techniques for determining causality at the moment, but none of them are recognized as the "gold standard" due to their flaws and differences **[38]**. Here, we've narrowed down a few key algorithmic techniques.

**5.2.1French imputability causality assessment Scale**

**Dangoumau et al.** first published this approach in 1978, and **Begaud et al.** refined it in 1985. It is the only technique for determining causality that distinguishes between internal and external accountability. French imputability is indicated by the following scores: extrinsic imputability score (B), intrinsic imputability score (I), chronological imputability score (C), and semiologic imputability score (S). When the provided information's details are considered along with the C and S ratings, the resultant imputability score (I), which stands for intrinsic accountability, is calculated. In order to estimate the extrinsic accountability, the B score is evaluated using the most recent scientific research that is currently available. France uses a single approach of imputability that was selected for maximal sensitivity at the expense of specificity **[39-40]**. The alert system employs this technique, which independently takes into account any recorded information as well as any drug a patient has taken. The data are examined in light of the national data bank when an alert is established. The use of a standard adverse drug reaction assessment system by all parties involved in the pharmacovigilance programme is the key benefit of this novel approach. Because the categories of criteria, such as "compatible," "suggestive," or "inconclusive," have never been properly defined, there is only partial reproducibility. Although imprecisely, the process of expert judgement is founded on the same deciding element that underlies algorithms.

**5.2.2Naranjo algorithm causality assessment scale**

In order to assess the causation between a adverse event and a prospective treatment medicine, the Naranjo Algorithm provides likelihood scores to a list of ten simple questions. Using terms and concepts like "definite," "probable," "possible," and "doubtful," it evaluates the causality in various clinical disorders. Based on the ultimate score determined after evaluating 10 questions, the negative reaction is categorized as a likelihood type. The type is "definite" if the total score is less than 9, "probable" if the total score is between 5-8, "possible" if the total score is between 1-4, and "doubtful" if the total score is less than 0 **(Table 5).** Reviews frequently compare the author's conclusions with ADR using the score generated by this algorithm following the assessment **[41].** When standardizing the cause analysis for ADR, the Naranjo scale and the WHO-UMC scale are compared.

**Table 5. Naranjo algorithm causality assessment scale**

|  |  |  |  |
| --- | --- | --- | --- |
| **Questions** | **Yes** | **No** | **Don’t know** |
| * Presence of previous conclusive report on adverse reaction.
 |  |  |  |
| * Did adverse event appear subsequent to administration of suspected drug?
 |  |  |  |
| * Did adverse event improve on drug discontinuation or on administration of specific antagonist?
 |  |  |  |
| * Did the adverse event reappear when the drug was re-administered?
 |  |  |  |
| * Are there any alternative causes other than the suspected drug that could have caused the reaction on their own?
 |  |  |  |
| * Did the adverse event reappear when a placebo was administered?
 |  |  |  |
| * Was the incriminated drug detected in toxic concentrations in blood (fluids)?
 |  |  |  |
| * Did the adverse event worsen on increasing the dose or decreased in severity with lower doses?
 |  |  |  |
| * Past history of any similar reaction to the same or similar drugs.
 |  |  |  |
| * Was the adverse event confirmed by objective evidence?
 |  |  |  |
| **Total score 0– Doubtful 1–4 Possible, 5–8 Probable, ≥9 Definite** |

**Method of Kramer et al. [17]**

This algorithm is relevant to a single clinical symptom that develops following the use of a single questionable medication. When numerous medicines are present, each is evaluated separately. The transparency of this algorithm is one of its benefits. However, to apply this strategy successfully, a certain amount of knowledge, experience, and time are needed **[42]**.

**5.2.3Balanced assessment method (Lagier et al.) [19]**

It grades case reports using a set of visual analogue scales (VAS) based on the likelihood that each criteria is met. The benefit of this approach is that each aspect is considered as a potential causative option rather than merely as a separate factor. Despite the fact that each case is examined by two different assessors, the assessment still strongly depends on the assessors' expertise. For an evaluation to be accurate, the evaluator must be an authority in the subject matter **[43]**.

**5.2.4Summary time plot (Castle et al.) [20]**

ADR pattern recognition was recommended to be carried out in an industrial setting. The graphic provides a timeline between the course of therapy and any probable side effects. When the causality criteria give sufficient information, the length of therapy and any potential adverse reactions are plotted with time on the x-axis and strength of the potential adverse reactions on the y-axis. This method cannot show causation because it just summarises the time factor along with other variables that are crucial to the drug-event relationship. However, the method is easy to apply, avoids using ambiguous terminology, and is effective even with a limited level of understanding **[44]**.

**5.2.5Ciba geigy method (Venulet et al.) [21]**

Numerous expert consensus sessions led to the creation of the "Ciba-Geigy method." Experts evaluated occurrences and determined causality on a VAS using their clinical opinion. This strategy was altered, and it was replaced with a 23-item checklist that was broken down into three sections: (i) keeping an eye on experience of physician (ii) unfavourable effects the patient has experienced in the past, and (iii) History of the current unfavourable reaction. There is a lot of consensus (62%) was found when this modified method was compared to the assessors' assessments. Even though the degree of dependability does not ensure validity **[45]**, this technique reflects the knowledge and experience of the evaluator as well as the type of ADR that is being examined.

**5.2.6Loupi et al. method [22]**

It was created to evaluate a drug's potential for teratogenicity. The medicine can be disregarded in the algorithm's initial parts (chrono-semiological axis) if it is not thought to be the cause of the aberration. The bibliographical data are weighted in the second part (bibliographical axis). The three inquiries consider the drug's chronology, any potential alternate aetiological options, and other bibliographical data to determine **causation [46].**

**5.2.7Roussel Uclaf causality assessment method (RUCAM)[7] [Danan G et al. 1993].**

The purpose of this therapy is to treat predetermined sickness conditions, like liver and skin damage. A retrospective investigation of the repeatability of this process among four specialists revealed a 37-99% agreement rate. Although it seems rather easy to use, this method is organ-specific. Therefore, the criteria must be established by a consensus of experts in each medical specialty and validated before it may be utilized in ADRs other than hepatic or dermatological damage **[47]**.

**5.2.8Maria and Victorino (M and V) scale [23]**

This scale was created by Maria and Victorino to identify drug-induced liver damage (DILI). Scores between 6 and 20 were used to convey probability, which was then separated into five causation levels (definite, scores of >17; probable, 14–17; plausible,10–13; unlikely, 6–9; excluded medication related hepatotoxicity). The accurate diagnosis of DILI is difficult and demands the assistance of qualified medical professionals. Even though it is well-known, it has certain gaps. The scale must be determined for each drug when there is suspicion of more than one substance. Calculating scores for other hepatic conditions using the M&V scale is difficult since it contains some questions that are exclusively applicable to immunoallergic hepatitis **[48].**

**5.2.9Drug Interaction Probability Scale (DIPS) [24]**

The concept originated with Horn et al. To evaluate drug interaction situations, the Drug Interaction Probability Scale (DIPS) is used. Ten questions with a "yes" or "no" response each are posed by the DIPS to provide a score indicating the possibility of a medication interaction **(Table 6).** The inquiries relate to the drug's pharmacological characteristics, potential interactions with other medications, and information specific to the patient. The approach was created to aid users in evaluating the negative effects caused by drug interactions as well as to function as a roadmap for further research into possible drug interactions. The only prerequisite is having a sufficient understanding of the implicated medications and the fundamental mechanisms of interaction **[49]**.

**Table 6. Questions for Drug Interaction Probability Scale**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| S. No | Question | Yes | No | NA |
|  | 'Are there previous credible reports of this interaction in humans?' |  |  |  |
|  | 'Is the observed interaction consistent with the known interactive properties of the precipitant drug?' |  |  |  |
|  | 'Is the observed interaction consistent with the known interactive properties of the object drug?' |  |  |  |
|  | 'Is the event consistent with the known or reasonable time course of the interaction (onset and/or offset)?' |  |  |  |
|  | 'Did the interaction remit upon de-challenge of the precipitant drug with no change in the object drug?' |  |  |  |
|  | 'Did the interaction reappear when the precipitant drug was re-administered in the presence of continued use of the object drug?' |  |  |  |
|  | 'Are there reasonable alternative causes for the event?' |  |  |  |
|  | 'Was the object drug detected in the blood or other fluids in concentrations consistent with the proposed interaction?' |  |  |  |
|  | 'Was the drug interaction confirmed by any objective evidence consistent with the effects on the object drug (other than drug concentrations from question 8)? |  |  |  |
|  | 'Was the interaction greater when the precipitant drug dose was increased or less when the precipitant drug dose was decreased?' |  |  |  |
| Total Score |
| Highly Probable: >8, Probable: 5- 8, Possible: 2- 4, Doubtful:"A NO answer presumes that enough information was presented so that one would expect any alternative causes to be mentioned. When in doubt, use Unknown or NA designation." |

**5.3Probabilistic or Bayesian methods**

The Bayesian technique transforms a prior probability of drug causality into a posterior probability using specific discoveries in a safety instance **[50].** A probability ratio is further divided into many elements (much like report-specific data, such as time sequence or re-challenge/dechallenge that helps to identify between sources of events). A posterior probability of drug causality is obtained by multiplying the numerous components out to get at the final conclusion **[51].** Each component is used to a certain group of case information. Multiple reasons can be evaluated simultaneously using this strategy. There is no restriction on the amount of report details that can be evaluated simultaneously using this method. It can be carried out using a spreadsheet on paper or online. As soon as additional evidence of the suspected ADR is discovered, our technique immediately produces mathematical and practical conclusions **[50].** It is regarded as the method for determining causation that makes the greatest sense **[52].**

**5.3.1Australian methodology [27] [Mashford ML et al. 1984].**

It was one of the first probabilistic methods to be applied. Conclusions are generated from internal data from case reports, such as time and laboratory data. In the assessment, prior information regarding the suspect-drug profile is purposefully left out. Making likelihood decisions only takes into account the probability of a causal relationship **[53]**.

**5.3.2Bayesian Adverse Reactions Diagnostic Instrument (BARDI):**

To overcome the numerous limitations imposed on expert judgement and algorithms, the Bayesian Adverse Reactions Diagnostic Instrument (BARDI) was developed **[54].** When comparing a drug's likelihood of producing an adverse event to another cause, the BARDI is employed to determine the likelihood. The posterior odds are what are known as. Six assessment subsets are taken into account when calculating the posterior odds factor; the prior odds subset deals with background epidemiologic or clinical trial data, while the other five likelihood ratio subsets deal with case-specific data.

The previous odds factor for a patient is calculated by contrasting the anticipated drug-attributable risk with the background risk of a particular adverse event in a population that shares key characteristics with the patient under consideration (such as a medical condition). The five likelihood ratios (LRs) take into account any information with differential diagnostic value in the areas of patient history (Hi), timing of the adverse event in relation to drug administration (Ti), characteristics of the adverse event (Ch), drug dechallenge (De), which refers to any signs, symptoms, or occurrences after drug withdrawal, and drug rechallenge (Re), or readministration of the suspected causal drug(s). The posterior odds are the result of these factors **[55].**

PsO = PrO × LR(Hi) × LR(Ti) × LR(Ch) × LR(De) × LR(Re)

On paper or a computer, a spreadsheet tool can be used to implement the Bayesian technique. It calculates and provides instant numerical and graphical feedback whenever new pieces of information pertaining to the suspected ADR are taken into account **[56].** Case reports are read, and descriptions that match reports from the literature are listed in order to calculate the prior likelihood. Also taken into account and indicated are factors that help distinguish potential causes. The software consists of two worksheets: one for case findings and one for scoring, which are used to impute case parameters. This method can assess more than two potential reasons at once, although it does require some experience to use. The spreadsheet enables quick computations and conversation while working **[57].**

**6.Evaluation of the causality of adverse reactions to vaccinations**

Every year, 2-3 million children's lives are thought to be saved worldwide thanks to immunizations. Approximately 1.7 million children still pass away from vaccine-preventable diseases each year, despite tremendous improvements in the field **[58].** In order to guarantee that children received the recommended set of vaccinations, the World Health Organization (WHO) launched the Expanded Programme on Immunization (EPI) in 1974. The EPI served as the inspiration for India's Universal Immunization Programme (UIP) in 1985 **[59].** The UIP now provides immunization services to the 26 million babies who comprise the largest birth cohort in history of the world, with over 100 million doses of vaccines administered annually to infants under 1 year old in the nation **[60-61]**.

Vaccines can cause adverse effects, which are most frequently fever and rash with more serious disorders like anaphylaxis happening extremely seldom **[62].** For the UIP-recommended vaccinations, the expected rate of serious AEFIs varies from 1 in 1000 doses for the Bacillus Calmette-Guérin vaccine to 1 in 2-3 million doses for the oral polio vaccine **[63].** India launched its National AEFI Surveillance Programme in 1986, and the majority of countries use passive AEFI surveillance. In 2005, India became the first nation to legally ratify a collection of operational rules for surveillance. Both in 2010 and again in 2015, the recommendations underwent updates that were modelled after those made to the WHO's international AEFI guidelines **[64].**

**7.Conclusion**

Both routine monthly reporting for all AEFIs and urgent reporting for serious and severe AEFIs are options in India. The typical facility-based Health Management Information System must receive monthly reports of all AEFIs, including mild, substantial, and severe events. Medical officers must notify the national monitoring programme of serious and severe AEFIs within 48 hours of receiving notification of the incident using the appropriate forms **[65].**

The evaluation of reported serious/severe AEFI's causality is one of the key components of an adverse event surveillance system. The job of completing the evaluation review of all reported AEFI cases has been delegated to the Causality evaluation panel. The formation of the AEFI secretariat and National AEFI Technical Collaborating Centre has allowed for the streamlined, progressive, more frequent, and more effective causality assessment approach.

Serious and severe AEFIs are more likely to attract media attention and have the potential to increase community concerns about vaccination safety. Such worries could trigger calls for a vaccine to be taken off the market if they are not properly evaluated and handled **[66].** To ensure the safety of vaccinations used in the field, thorough investigations of serious and severe AEFIs must be carried out promptly.

**References**

1. Lazarou et al, Adverse Drug Reactions in hospitalized patients. JAMA.1998; Vol 279:1200-1205.
2. Lazarou J, Pomeranz BH, Corey PN: Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. *JAMA.* 1998;279(15):1200–5.
3. Stausberg J. International prevalence of adverse drug events in hospitals: an analysis of routine data from England, Germany, and the USA. BMC Health Serv Res 2014;14:125.
4. Pirmohamed M, James S, Meakin S et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ 2004;329:15-9.
5. Giardina C, Cutroneo PM, Mocciaro E et al. Adverse drug reactions in hospitalized patients: results of the FORWARD (Facilitation of Reporting in Hospital Ward) study. Front Pharmacol 2018;11:350.
6. Patel TK, Patel PB. Mortality among patients due to adverse drug reactions that lead to hospitalization: a meta-analysis. Eur J Clin Pharmacol 2018;74:819-32.
7. Patel NS, Patel TK, Patel PB, Naik VN, Tripathi CB. Hospitalizations due to preventable adverse reactions-a systematic review. Eur J Clin Pharmacol 2017;73:385-98.
8. Kongkaew C, Noyce PR, Ashcroft DM. Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann Pharmacother 2008;42:1017-25.
9. Doshi MS, Patel PP, Shah SP, Dikshit RK. Intensive monitoring of adverse drug reactions in hospitalized patients of two medical units at a tertiary care teaching hospital. J Pharmacol Pharmacother 2012; 3:308-13.
10. Patel TK, Patel PB. Incidence of adverse drug reactions in Indian hospitals: a systematic review of prospective studies. Curr Drug Saf 2016; 11:128-36.
11. Pande S. Causality or Relatedness Assessment in Adverse Drug Reaction and Its Relevance in Dermatology. Indian J Dermatol. 2018 Jan-Feb;63(1):18-21.
12. Sandberg A, Salminen V, Heinonen S, Sivén M. Under-Reporting of Adverse Drug Reactions in Finland and Healthcare Professionals’ Perspectives on How to Improve Reporting. Healthcare. 2022; 10(6):1015.
13. World Health Organization/Uppsala Monitoring Centre (2017) [http://www.who-umc.org](http://www.who-umc.org/).
14. Lindquist M, Ståhl M, Bate A, Edwards IR, Meyboom RH. A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database. Drug Saf. 2000 Dec;23(6):533-42. doi: 10.2165/00002018-200023060-00004. PMID: 11144660.
15. Meyboom RHB, Royer RJ. Causality Classification in Pharmacovigilance Centres in the European Community. Pharmacoepidemiology and Drug Safety 1992; 1:87-97.
16. Meyboom RHB. Causal or Casual? The Role of Causality Assessment in Pharmacovigilance. Drug Safety 17(6): 374-389, 1997.
17. Agbabiaka TB, Savović J, Ernst E. Methods for causality assessment of adverse drug reactions: A systematic review. Drug Saf. 2008;31:21–37.
18. Davies EC, Rowe PH, James S, Nickless G, Ganguli A, Danjuma M, et al. An investigation of disagreement in causality assessment of adverse drug reactions. Pharm Med. 2011;25:17–24.
19. Ihtisham K, Ramanujam B, Srivastava S, Mehra NK, Kaur G, Khanna N, Jain S, Kumar S, Kaul B, Samudrala R, Tripathi M. Association of cutaneous adverse drug reactions due to antiepileptic drugs with HLA alleles in a North Indian population. Seizure. 2019 Mar;66:99-103. doi: 10.1016/j.seizure.2019.02.011. Epub 2019 Feb 20. PMID: 30826555.
20. Manjunath G, Sheetal N, Pooja S, Neelkantreddy P, Snehasri Y. Carbamazepine Induced Stevens - Johnson Syndrome: A Case Report. Indian Journal of Pharmacy Practice, Vol 11, Issue 3, Jul-Sep, 2018.
21. Rzany B, Correia O, Kelly JP, Naldi L, Auquier A, Stern R. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions. Lancet. 1999 Jun 26;353(9171):2190-4. doi: 10.1016/s0140-6736(98)05418-x. PMID: 10392983.
22. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–45. [PubMed: 7249508]
23. Srinivasan R, Ramya G. Adverse drug reaction-causality assessment. Int J Res Pharm Chem 2011;1:2231-781.
24. Roujeau JC. The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: A clinical classification. J Invest Dermatol 1994;102:28S-30S.
25. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993;129:92-6.
26. Khosama, H., Budikayanti, A., Khor, A. H. P., Lim, K. S., Ng, C. C., Mansyur, I. G., Harahap, A., Ranakusuma, T. A. R., & Tan, C. T. (2017). HLA-B\*1502 and carbamazepine induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Indonesia. *Neurology Asia*, *22*(2), 113-116.
27. Danan G, Benichou C; Causality assessment of adverse reactions to drugs- i. a novel method based on the conclusions of international consensus meetings: application to druginduced liver injuries. J clin epidemiol., 1993; 46(1): 132-142.
28. Blanc S, Leuenberger P, Berger JP, Brooke EM, Schelling JL; Judgments of trained observers on adverse drug reactions. Clin Pharmacol Ther., 1999; 25: 493-498.
29. Taofikat BA, Savovi J, Ernst E; Methods for Causality Assessment of Adverse Drug Reactions A Systematic Review. Drug Safety, 2008; 31(1): 21-37.
30. Hoskins RE, Mannino S. Causality assessment of adverse drug reactions using decision support and informatics tools. Pharmacoepidemiology and Drug Safety, 1992; 1: 235-249.
31. Arimone Y, Begaud B, Miremont-Salame G, FourrierReglat A, Moore N, Molimard M, et al. A new method for assessing drug causation provided agreement with experts judgment. Journal of Clinical Epidemiology, 2006; 59: 308-314.
32. Wiholm BE. The Swedish drug-event assessment methods. Special workshop- regulatory. Drug Information Journal, 1984; 18: 267-9.
33. World Health Organization (WHO), Uppsala Monitoring Centre [Internet]. The use of the WHO-UMC system for standardized case causality assessment. Available from: http://www.who-umc.org/graphics/4409.pdf.
34. Rehan HS, Chopra D, Kakkar A; Physician's guide to pharmacovigilance: Terminology and causality assessment. European Journal of Internal Medicine, 2009; 20: 3-8.
35. Kumar P, Clark M; Clinical medicine. 8th edition, Philadelphia: Elseviers Saunders, 2012.
36. Lanctot KL, Naranjo CA; Computer-assisted evaluation of adverse events using a Bayesian approach. J Clin Pharmacol., 1994; 34: 142- 147.
37. Frick PA, Cohen LG, Rovers JP; Algorithms used in adverse drug event reports: a comparative study. Ann of Pharmacother., 1997; 31: 164-167.
38. Macedo AF, Marques FB, Ribeiro CF, Texeira F. Causality assessment of adverse drug reactions: comparison of the results obtained from published decisional algorithms and from the evaluations of an expert panel. Pharmacoepidemiol Drug Saf., 2005; 14: 885- 890.
39. Dangoumau J, Evreux JC, Jouglard J. Méthode d’imputabilité des effets indésirables des médicaments. Therapie 1978; 33: 373-81.
40. Begaud B, Evreux JC, Jouglard J, et al. Imputabilité des effets inattendus ou toxiques des médicaments. Actualisation de la méthode utilisée en France. Therapie 1985; 40: 111-8.
41. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA et al.; A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther., 1981; 30: 239-245.
42. Kramer MS, Leventhal JM, Hutchinson TA, Feinstein AR; An algorithm for the operational assessment of adverse drug reactions: I. Background, description, and instructions for use. JAMA, 1979; 242: 623-632.
43. Lagier G, Vincens M, Castot A; Imputability in drug monitoring: principles of the balanced drug reaction assessment method and principal errors to avoid. Therapie, 1983; 38: 303-318.
44. Castle WM; Assessment of causality in industrial settings. Drug Inf J., 1984; 18: 297- 302.
45. Venulet J, Ciucci A, Berneker GC; Standardised assessment of drug-adverse reaction associations: rationale and experience. Int J Clin Pharmacol Ther Toxicol., 1980; 18: 381-388.
46. Loupi E, Ponchon AC, Ventre JJ; Imputability of a teratogenic effect [in French]. Therapie, 1986; 41: 207-210.
47. Danan G, Benichou C; Causality assessment of adverse reactions to drugs- i. a novel method based on the conclusions of international consensus meetings: application to druginduced liver injuries. J clin epidemiol., 1993; 46(1): 132-142.
48. Maria VA, Victorino RM; Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology, 1997; 26: 664-669.
49. Horn JR, Hansten PD, Chan LN; Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother., 2007; 41: 674-680.
50. Hutchinson T, Dawid A, Spiegelhalter D. Computerized aids for probabilistic assessment of drug safety: A spreadsheet program. Drug Information Journal, 1991; 25: 29-39.
51. Benichou C, Danan G. Causality assessment in the European pharmaceutical industry: presentation of the preliminary results of a new method. Drug Information Journal, 1992; 26: 589-92.
52. Ennis M, Ohmann C, Lorenz W, et al. Prediction of risk for pseudoallergic reactions and histamine release in patients undergoing anaesthesia and surgery: a computer-aided model using independence-Bayes. Agents Actions, 1988; 23: 366-9.
53. Mashford ML; The Australian method of drugevent assess ment. Special Workshop – regulatory. Drug Inf J., 1984; 18: 271-273.
54. Naranjo CA, Lanctot KL; A consultant‟s view on the role of Bayesian differential diagnosis in the safety assessment of pharmaceuticals. Drug Inf J., 1992; 26: 593-601.
55. Lanctot KL, Naranjo CA; Computer-assisted evaluation of adverse events using a Bayesian approach. J Clin Pharmacol., 1994; 34: 142- 147.
56. Hutchinson TA, Dawid AP, Spiegelhalter DJ, Cowell RG, Roden S; Computerized aids for probabilistic assessment of drug safety: I. A spreadsheet program. Drug Inf J., 1991; 25: 29-39.
57. Benichou C, Danan G; Causality assessment in the European pharmaceutical industry: presentation of the preliminary results of a new method. Drug Inf J., 1992; 26: 589-592.
58. World Health Organization. World immunization week [Internet]. Immunization, Vaccines Biol. 2012 [cited 2017 May 2]. Available from: http://www.who.int/immunization/newsroom/events/immu nization\_week/2012/further\_information/en/index1.html
59. Immunization Technical Support Unit. Background of immunization program in India [Internet]. [cited 2018 Apr 2]. Available from: http://www.itsu.org.in/about-UIP-in-india
60. Dasajh AC Universal immunization programme [Internet]. 2015 [cited 2015 Nov 5]. Available from: http://nrhmchd.gov.in/uip.htm
61. Government of India. National vaccine policy. New Delhi, India: Ministry of Health & Family Welfare; 2011.
62. Asturias EJ, Wharton M, Pless R, et al. Contributions and challenges for worldwide vaccine safety: The Global Advisory Committee on Vaccine Safety at 15 years. Vaccine. 2016;34:3342–3349.
63. World Health Organization. Information for health-care workers - managing adverse events [Internet]. 2018. [cited 2018 Apr 2]. Available from: http://www.who.int/vaccine\_safety/initiative/detec tion/managing\_AEFIs/en/index4.html
64. World Health Organization. Global manual on surveillance of adverse events following immunization. Geneva, Switzerland: WHO Document Production Services; 2016.
65. Ministry of Health and Family Welfare. Government of India. Adverse events following immunization: surveillance and response operational guidelines. New Delhi: Ministry of Health and Family Welfare, Government of India; 2015.
66. Puliyal J, Phadke A. Deaths following pentavalent vaccine and the revised AEFI classification. Indian J Med Ethics. 2017;6:1–2.